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Objectives: To test the hypothesis that familial Mediterranean fever (FMF)-associated
autoinflammation may exaggerate the tendency toward adaptive immunopathology or
spondyloarthritis (SpA)-associated disorders including major histocompatibility complex
(MHC) class I associated disorders but not classical MHC class II-associated disorders
that exhibit transplacental autoimmunity including myasthenia gravis and pemphigus.
Methods: Seven thousand seven hundred forty-seven FMF patients and 10,080
age- and sex-matched controls in the Clalit Health Services medical database were
identified and compared in terms of prevalence of SpA-associated disorders. We
also evaluated four classical and strong MHC class II-associated disorders, namely,
pemphigus vulgaris, myasthenia gravis, sarcoidosis, and pernicious anemia, to ascertain
whether such associations with SpA-spectrum disease were specific or merely reflected
the non-specific consequences of innate immune system activation on driving divergent
types of immunity. The diagnosis of FMF was based on the medical records and not
genetically proven.
Results: FMF showed a strong association with MHC class I-related diseases: odds
ratio (OR) of 28.58 [95% confidence interval (95% CI), 6.93–117.87; p < 0.0001]
for Behçet’s disease, OR of 10.33 (95% CI, 4.09–26.09; p < 0.0001) for ankylosing
spondylitis, and OR of 1.67 (95% CI, 1.19–2.33; p = 0.0029) for psoriasis. For weakly
MHC class I-linked diseases, an OR of 3.76 (95% CI, 2.48–5.69; p < 0.0001) for Crohn’s
disease and OR of 2.64 (95% CI, 1.52–4.56; p = 0.0005) for ulcerative colitis were
found. No association was found between FMF and the four MHC class II-associated
autoimmune disorders.
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Conclusion: FMF patients are associated with increased risk of SpA-related disease
diagnosis including MHC-I-opathies but not MHC-II-associated autoimmune diseases,
suggesting that tissue-specific dysregulation of innate immunity share between FMF and
SpA spectrum disorders may drive adaptive immune MHC class I-associated conditions.
Keywords: Familial Mediterranean fever, spondyloarthritis, Crohn’s disease, ulcerative colitis, MHC-I
INTRODUCTION
Familial Mediterranean fever (FMF) is one of the paradigmatic
hereditary autoinflammatory disorders, caused by point
mutations, either non-sense or missense, in the Mediterranean
fever (MEFV) gene, generally inherited in an autosomal recessive
way (1). It is characterized by brief, painful, recurrent episodes
of skin rash (usually, erysipelas-like erythema), peritonitis,
pleuritis, synovitis, arthritis, and, rarely, pericarditis and
meningitis, accompanied by fever.
Historically, Behcet’s disease (BD), Crohn’s disease (CD),
ulcerative colitis (UC), psoriasis, and ankylosing spondylitis (AS)
were classified under the spondyloarthritis (SpA) umbrella term
(2). FMF and the SpA group of disorders share an association
with disease localization to site of physical stress or microdamage
with innate immune activation at such sites as a primary driver
of immunopathology (3, 4).
With the development of the immunological disease
continuum model of inflammation against self, these disorders
were placed as intermediates between autoinflammation and
autoimmune boundary of self-directed inflammation (5).
Recently, we pointed out how BD, psoriasis, anterior uveitis, and
AS fitted under the unifying umbrella term of “MHC-I-opathies,”
due to shared immunopathogenetic mechanisms, a common
association with tissue-specific microdamage, disturbed and
impaired barrier function of skin, mouth and gut, and role of
innate lymphoid cells surveillance in the context of IL23–IL17
axis-related genetic polymorphisms (5). Although CD and UC
share many of these features, specific major histocompatibility
complex (MHC) class I associations at the population level are
very weak, suggesting a greater contribution of innate immunity
at the population level (5, 6).
Several case series and small studies have reported potential
associations between FMF and SpA-related diseases and
indeed other rheumatic disorders including rheumatoid arthritis
(RA) (7–9). However, the RA association with MEFV-related
mutations may specifically be with antibody negative or
“autoinflammatory-type RA” (5). We utilized a large cohort of
FMF cases where the disease is known to represent a tissue-
specific innate immunopathology (10). We then looked at
the association between the “MHC-I-opathy”-related conditions
including AS, psoriasis, and BD and, at the population level non-
MHC class I SpA-associated diseases, namely, CD and UC, all
of which are also associated with tissue-specific dysregulation
as key pathological drivers. We also looked at MHC class II-
associated diseases, especially autoantibody-associated diseases
to ascertain whether such associations with SpA spectrum disease
were specific or merely reflected the non-specific consequences




The study protocol of the current investigation was approved by
the Ethical Committee of the Clalit Health Services, located at the
Soroka Medical Center, Beer-Sheva, Israel.
Study Population
Data were collected from the Clalit Health Services Database,
the largest state-mandated health service organization in Israel.
The data undergo an extensive series of cross-check and quality
verification by comparing diagnoses from various sources. The
validity of the data was verified to be high, as shown in previously
published studies (11–14). Wide-scale epidemiological studies
can be conducted in real time on heterogeneous groups using
advanced, massive data-mining techniques from the database.
The FMF patients were identified based on at least two
diagnosis of FMF in their medical records given by general
practitioner, primary care physician, or a specialist. FMF has
ethnic predilection to nations of the Mediterranean region,
being frequently observed among Turkish, Jewish, Arabic, and
Armenian communities. The Clalit Health Services database
comprises ∼7,700 patients. All FMF patients detected in the
Clalit Health Services database were considered eligible and, as
such, were enrolled in the present study. The control group
involved randomly selected Clalit Health Services enrollees
excluding the patients with an established diagnosis of FMF.
Controls were age- and sex-matched to cases.
Similarly to FMF, the diagnosis of SpA-related diseases (CD,
UC, psoriasis, BD, and AS), included patients with such certified
diagnosis in their medical records at least twice as entered by
specialists in the Clalit Health Services registry. We also selected
MHC class II and autoantibody-associated diseases (pernicious
anemia, myasthenia gravis, and pemphigus vulgaris) and the
MHC class II non-autoantibody-associated disease (sarcoidosis)
to evaluate whether FMF was non-specifically associated with
an array of inflammatory disorders or linked to diseases where
tissue-specific innate immune dysregulation is a key early feature.
Data collected from the Clalit Health Services database included
relevant sociodemographic and clinical information such as age,
gender, socioeconomic status (SES), body mass index (BMI),
and smoking status. More in detail, SES was defined according
to the poverty index of the member’s residence area. Briefly,
poverty index is computed from several parameters including
household income, education, and other factors, which are
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clustered together and ranked. The composite index ranged from
1 to 20 with 1 as the lowest SES.
Statistical Analyses
Before processing the data, they were visually inspected for
potential outliers. Normality of data distribution was verified
applying the D’Agostino-Pearson omnibus test. Continuous
variables were computed as mean± standard deviation, whereas
categorical parameters were expressed as percentages.
The occurrence of FMF and of SpA spectrum disorders was
compared between FMF patients and controls in the selected
study sample. The chi-squared test was used to assess the
distribution of categorical variables, while the t-test and ANOVA
were applied for continuous variables. Moreover, the association
between FMF and SpA-associated disorders was assessed using
a multivariate logistic regression model and a multivariate
Cox proportional-hazards regression model, both adjusted for
possible confounding factors.
Analyses regarding survival rates were performed using the
Kaplan–Meier curves, the log-rank test, and the multivariate Cox
proportional-hazards method to detect factors associated with
increased all-cause riskmortality, with adjustment for risk factors
where appropriate.
All statistical analyses were performed using the commercial
software “Statistical Package for the Social Sciences” forWindows
(SPSS version 24.0, SPSS Inc., IBM, USA). Graphs were
generated utilizing the commercial software MedCalc version
17.9.7 for Windows (MedCalc Software bvba, Ostend, Belgium;
http://www.medcalc.org; 2017). For all analyses, figures with p <
0.05 were considered statistically significant.
RESULTS
Basic Characteristics of the Study
Population
The current study included 7,747 FMF patients and 10,080 age-
and sex-matched controls. The two groups did not differ in terms
of BMI, while they differed in terms of SES (p= 0.0200), with low
and medium strata being overrepresented among FMF patients.
Smokers were more present among FMF patients (2,412, 31.1%,
vs. 2,588, 25.7%, p < 0.0001).
The Proportion of the Different
SpA-Related Disorders and
MHC-I-Opathies in FMF and Controls
The SpA spectrum disorder diagnosis was significantly higher
in FMF patients compared with controls (326 cases, 4.2%, vs.
129 cases, 1.3%, p < 0.0001) (Figure 1A). For further details, the
reader is referred to Figure 1A and Table 1.
The Risk of SpA-Related Disorder and
MHC-I-Opathy Diagnosis in FMF Patients
At the univariate analysis, FMF had a 3.2-fold higher chance
of being diagnosed with a SpA-related disorders compared with
controls. After adjusting for confounders, FMF patients had an
odds ratio (OR) of 3.27 [95% confidence interval (95% CI),
2.62–4.10; p < 0.0001] of developing SpA-related disorder.
More specifically, an increased risk of an OR of 28.58
(95% CI, 6.93–117.87; p < 0.0001) for BD, an OR of 10.33
(95% CI, 4.09–26.09; p < 0.0001) for AS, and an OR
of 1.67 (95% CI, 1.19–2.33; p = 0.0029) for psoriasis, an
OR of 3.76 (95% CI, 2.48–5.69; p < 0.0001) for CD, and
an OR of 2.64 (95% CI, 1.52–4.56; p = 0.0005) for UC
was found.
The multivariate Cox proportional-hazards regression
analysis confirmed this link: a hazard ratio (HR) of 27.92 (95%CI,
6.77–115.13; p < 0.0001) for BD and HR of 9.72 (95% CI, 3.85–
24.55; p < 0.0001) for AS, HR of 1.62 (95% CI, 1.16–2.26; p =
0.0046) for psoriasis, HR of 3.68 (95% CI, 2.43–5.57; p < 0.0001)
for CD, and HR of 2.52 (95% CI, 1.46–4.36; p = 0.0009) for UC
was found.
A Lack of Association Between FMF and
Strong MHC Class II-Associated Diseases
To assess whether FMF was associated with all autoimmune
diseases regardless of the mechanoinflammatory SpA
environment (18) and MHC class I components, we selected
four strongly associated MHC class II-related diseases, and no
association was found with FMF (Figure 1B). Indeed, FMF
patients had an OR of 1.67 (95% CI, 0.28–10.05; p = 0.5763) for
pemphigus vulgaris and an OR of 1.80 (95% CI, 0.30–10.84; p
= 0.5208) for myasthenia gravis, noting that both these diseases
may exhibit transplacental autoimmunity. Likewise, an OR of
1.91 (95% CI, 0.86–4.21; p = 0.1109) for sarcoidosis, and an OR
of 0.65 (95% CI, 0.19–2.23; p = 0.4896) for pernicious anemia
was computed.
The Impact of MHC-I-Opathy Diagnosis on
the Mortality of FMF Patients
All-cause mortality was statistically higher in FMF patients than
controls (366 deaths, 4.7%, vs. 341 deaths, 3.4%, p < 0.0001).
At the Cox multivariate survival analysis, SpA-related disorder
or MHC-I-opathy diagnosis in FMF patients was not associated
with increased all-cause mortality with HR of 0.96 (95% CI,
0.55–1.68; 0.8800) (Figure 2). However, stratifying according
to the specific SpA-related disorder, FMF patients with CD
had a risk of death of 2.32 (95% CI, 1.09–4.93; p = 0.0291)
compared to those without CD. Further details are reported
in Table 2.
DISCUSSION
To the best of our knowledge, the current study is the first
to systematically explore the association between various SpA-
associated diseases (CD, UC, BD, psoriasis, and AS) and also
classical autoimmune diseases and FMF. It offers a robust
epidemiological evidence that corroborates the concept of MHC-
I-opathies and suggests that FMF may share some common
mechanisms and pathways. Specifically, the stronger association
between FMF and BD and AS and psoriasis points toward
secondary adaptive immune activation at sites of MEFV-
related tissue-specific dysregulation. This association extends to
inflammatory bowel disease (IBD) including CD and UC that
form part of the SpA spectrum. Furthermore, a lack of association
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FIGURE 1 | The link between familial Mediterranean fever (FMF) patients and major histocompatibility complex (MHC) class I-associated disorders (A) compared to
MHC class II-associated disorders (B). Unlike the MHC class I-associated disorders where a link with FMF is consistently reported the situation for MHC class II
diseases is less clear. FMF has been linked to RA, but ∼30% of RA cases are seronegative, and some of these may be innate immune mediated (15). Weak
associations between FMF and MS have been reported, but putative-disease-associated autoantibodies remain controversial. The other classical autoimmune
diseases with MHC class II and autoantibody associations have not been linked to MEFV mutations. *These findings are based on the references (16, 17).









Age (mean ± SD) 38.43 ± 19.62 37.69 ± 19.55 39.38 ± 19.68 NS
Age at diagnosis (mean ± SD) 26.41 ± 18.41 25.67 ± 18.35 27.37 ± 18.45 NS
Gender (female; %) 9,000 (50.5%) 5,121 (50.8%) 3,879 (50.1%) NS
BMI (mean ± SD) 24.81 ± 63.91 24.42 ± 50.61 25.30 ± 77.41 NS
SES (n; %)a p = 0.02
Low 8,370 (50.6%) 4,729 (50.3%) 3,641 (51.1%)
Medium 5,609 (33.9%) 3,153 (33.5%) 2,455 (34.5%)
High 2,548 (15.4%) 1,524 (16.2%) 1,024 (14.4%)
Smoking (n; %) 5,000 (28.0%) 2,588 (25.7%) 2,412 (31.1%) <0.0001
SpA-related disorders 455 (2.6%) 129 (1.3%) 326 (4.2%) <0.0001
Psoriasis 156 (0.9%) 66 (0.7%) 90 (1.2%) 0.0003
Behçet’s disease 51 (0.3%) 2 (0.02%) 49 (0.6%) <0.0001
Ankylosing spondylitis 53 (0.3%) 6 (0.1%) 47 (0.6%) <0.0001
Crohn’s disease 130 (0.7%) 35 (0.3%) 95 (1.2%) <0.0001
Ulcerative colitis 65 (0.4%) 20 (0.2%) 45 (0.6%) <0.0001
All-cause mortality (n; %) 707 (4.0%) 341 (3.4%) 366 (4.7%) <0.0001
aData available for 92.7% of the population.
between FMF and those diseases with strong MHC class II
associations was observed supporting the concept that these
latter disorders are often exclusively linked to central tolerance
failure; hence, the impact of MEFV mutations is much less
or non-existent.
With respect to BD, single nucleotide polymorphisms
including ERAP1, IL23R, IL10, and MEFV variations confirm
shared susceptibility genes and inflammatory pathways with
SpA-related disorders (19). ERAP1, IL23R, and different MHC
class I associations have also been reported for AS, psoriasis,
and uveitis (20). We previously reported that the proportion of
FMF in patients with BD is significantly higher (5.83 vs. 0.23%,
respectively, p < 0.001) (21).
Regarding FMF and AS, a meta-analysis (22) found that
MEFV M694V mutation has a role in susceptibility to AS, with
a pooled OR of 3.33 (95% CI, 2.13–5.21). A recent review of the
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FIGURE 2 | The impact of the presence of spondyloarthritis (SpA) diagnosis
on familial Mediterranean fever (FMF) patients’ survival.
literature (23) reported a highly variable prevalence of AS among
FMF patients, ranging from 0.75% (24) to 100% (25), even though
an overall significant association betweenMEFV gene mutations
and AS has been documented. Concerning psoriasis, there is
dearth of evidences, besides anecdotal reports of an association
with FMF (8). A study with a sample of 351 FMF found an
increased frequency of psoriasis (3.7%) compared to the normal
population (26).
A few small studies have investigated the link between FMF
and IBD and provided contrasting findings. For instance, Fidder
et al. (27) found that the co-occurrence of FMF and CD
is characterized by unique clinical features. By means of an
extensive computerized search, the authors were able to identify
seven patients with concomitant CD and FMF, which is more
than the expected prevalence rate in the general population
(p= 0.03) (27). In particular, CD presented at a significantly later
age of incidence in the FMF-CD group (40.6± 10.0 years vs. 26.2
± 11.4 years; p < 0.004), whereas FMF was characterized by a
higher attack frequency (p < 0.05) and increased prevalence of
amyloidosis (p < 0.02). On the other hand, other studies (28)
could not detect any statistically significant association between
FMF gene mutations and IBD phenotypic characteristics. Akyuz
et al. (29) found a higher overallMEFV variation frequency in the
IBD (25.5%) patients compared with controls (9.9%, p = 0.006).
These findings suggest that MEFV variations may represent an
additional susceptibility factor for IBD, especially if the carrier
rate is high.
We found no association between FMF and four MHC
class II-associated disorders, namely, pemphigus vulgaris,
myasthenia gravis, sarcoidosis, and pernicious anemia.
Collectively, these disorders are strongly linked to CD4T-cell
cell immunopathology including follicular helper T-cell germinal
center support for autoantibody formation and Th1-type T-cells
responses for delayed type IV immune hypersensitivity reactions
in sarcoidosis. We included two autoimmune disorders that
show transplacental transmission, indicating that pathogenic
autoantibodies are a sine qua non for disease expression and also
suggesting that a role for physically stressed target tissues does
not play a role in disease onset, unlike SpA. However, someMHC
TABLE 2 | The impact of different spondyloarthritis (SpA)-related disorders
including MHC-I-opathies on the mortality of familial Mediterranean fever (FMF)
patients.
Variable HR 95% CI p value
SpA-related disorders 0.96 0.55–1.68 0.8800
Behçet’s disease 0.44 0.06–3.14 0.4123
Psoriasis 0.72 0.23–2.25 0.5686
Ankylosing spondylitis 1.00 1.00–1.00 0.9561
Crohn’s disease 2.32 1.09–4.93 0.0291
Ulcerative colitis 1.06 0.26–4.25 0.9393
Bold value is statistically significant.
class II association diseases including rheumatoid arthritis (RA)
and multiple sclerosis (MS) were previously reported to be linked
to FMF (16, 17). Nevertheless, it is entirely possible that the
MEFV association with RA is in autoantibody-negative disease
or an autoinflammatory variant of disease (15). Previous studies
have also shown a link between MS and FMF and reported that
homozygosity for the M694V MEFV mutation may aggravate
the phenotype of MS (16). Although MS is autoimmune in
nature, there is plentiful evidence for tissue-specific neuronal
damage or degeneration contributing to the phenotype, but this
is controversial (30).
Several plausible mechanisms can be behind the link between
FMF and SpA-related disorders and MHC-I-opathy. First, these
disorders share key features with FMF such as disease localization
to sites of mechanical stress, either at barrier surfaces or internal
sites. Furthermore, there is an excessive response to normal levels
of stress occurring at barrier surfaces or at sites of microdamage,
which lead to activations of innate immunity components and in
later phases of the adaptive immunity and tissue target damage
(20). Furthermore,MEFV mutations have been reported by some
case reports to be involved also in some SpA-related disorders,
mainly those named “MHC-I-opathies” such as BD, AS, and
psoriasis (22, 31, 32).
It is generally held that anti-IL-1 therapy is not effective for
SpA, which is largely based on a proof of concept study in a group
of patients that generally had normal CRP values—a biomarker,
that when elevated, predicts response to biological therapy in SpA
(33). IL-1 pathway SNPs have been linked to AS (34), and another
study showed that the IL-1 antagonist is moderately effective in
controlling the clinical manifestations of AS (35). It would be
interesting to ascertain whether subjects with resistant AS and
SpA showed responses with full IL-1 blockade with monoclonal
antibody therapy against IL-1 in populations with a high carriage
rate of theMEFV gene.
Our study has some limitations, especially the lack of some
genetic and clinical characterization of the FMF patients in
terms of MEFV variations, clinical symptoms, and severity of
disease, which might potentially impact on disease course and
its association with other comorbidities. The impact of the
heterozygous carriage in asymptomatic subjects without FMF
and its risk for MHC-I-opathies needs consideration. Given the
link between FMF and pyrin inflammasome pathway activation
and dysregulated production of IL-1beta in particular, these
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findings might point toward a role for IL-1 pathway blockade
in SpA subjects in populations that have FMF or carry MEFV
heterozygous mutations, but this needs further study.
In conclusion, our study showed a statistically significant
association between FMF and the risk of developing SpA group
of diseases including those termed as MHC-I-opathy but not
those with a strong MHC class II association (36). This could
have important practical implications for the elucidation of
etiopathogenesis of MHC-I-opathy disorders and may pave the
way for future therapeutic strategies in these cases.
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